HDT Bio, a Seattle-based biotech company, is taking steps to address rising COVID-19 cases in India by introducing a new vaccine candidate that works similar to the Pfizer and Moderna vaccines. The goal is to produce and manufacture the vaccine in India to help keep prices down and speed up the approval process.
According to HDT Bio CEO, Steven Reed: “Other variants can be readily incorporated. So, this is the beginning of the process. Our second generation, which will follow very quickly after the first one, will be the combination of variants as needed. And that’s what we’re most excited about – having a multi variant vaccine platform that’s made locally, delivered locally, used locally.”